A Phase 1 interventional study of NDI-5001 in Diabetes Insipidus, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Recruiting at 3 sites in United States. Open to male participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Diabetes Insipidus with a site in United States — 7 open to participants now, 7 under way, none of them phase 3. Diabetes Insipidus · United States.
Among the 51 studies in Diabetes Insipidus with a site in United States, this one is the 30th largest by planned enrollment of the 41 interventional ones that give a count, is the only one that started in 2026, is one of 7 in phase 1, and was the 51st registered.
191 studies on the registry are indexed under Diabetes Insipidus; 35 are open to participants now.
Browse Diabetes Insipidus studies →7 of the 51 studies in Diabetes Insipidus with a site in United States are open now. Recruiting first, the newest first:
The Cleveland Clinic · Sites in United States
Ages 18+
Children's Oncology Group · Sites in United States, Australia, Canada
Ages 3–29
Jason Sperry · Sites in United States
Ages 18–90
University of Maryland, Baltimore · Sites in United States
Ages 18–65 · Healthy volunteers
University of Chicago · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 30 Diabetes Insipidus studies recruiting now, 16 (53%) set no upper age limit and 11 (37%) stop at 75 or younger; 4 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 55 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 8 · Phase 3 4 · Phase 4 10
First in 1995; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is below the median of 77 across 118 interventional studies indexed under Diabetes Insipidus.
Median enrollment 40 across the 41 interventional studies, 101 across the 9 observational. Of the 39 that completed or were terminated, 16 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 51 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
Otsuka Holdings Co., Ltd. has 4 studies filed under Diabetes Insipidus — fewer than ten, so there is no comparison to draw.
5 of the studies in Diabetes Insipidus with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03446456University of Maryland, BaltimoreVasopressin and Pain Perception in the Brain | 2026-12-31 |
| NCT05958342Jason SperryCAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial | 2027-03 |
| NCT02841553Washington University School of MedicineWolfram Syndrome and WFS1-related Disorders International Registry and Clinical Study | 2027-04 |
| NCT06709573The Cleveland ClinicEarly Versus Late Adjunctive Vasopressin in Septic Shock | 2027-05-01 |
| NCT07525960Otsuka Pharmaceutical Development & Commercialization, Inc.A Study in Adult Males With X-linked Congenital Nephrogenic Diabetes Insipidus to Test the Effects of NDI-5001 Given for Multiple Days and to Test How NDI-5001 is Tolerated and Taken up in the Body | 2027-08-25 |
Add all 5 to your calendar (.ics) → With an account.
Among the 51 studies in Diabetes Insipidus with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NDI-5001 administered as a capsule following daily oral dosing in adult males with X-linked congenital nephrogenic diabetes insipidus (NDI) due to vasopressin receptor Type 2 (V2R) mutations.
The criteria were revised on the registry on Oct 20, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Note: Other protocol-specified inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive NDI-5001, orally, once daily (QD), for 9 consecutive days starting on Day 1.
Drug: NDI-5001
Capsule.
Percentage Change From Baseline in 24-Hour Urine Volume (Uvol)
Time frame: Up to Day 10
Percentage Change From Baseline in Spot Urine Osmolality (Uosm)
Time frame: Up to Day 10
Change From Time-Matched Baseline in Uvol
Time frame: Up to Day 10
Change From Time-Matched Baseline in Uosm
Time frame: Up to Day 10
Change From Baseline in 24-Hour Uosm
Time frame: Up to Day 10
Correlation Coefficient Between 24-Hour Uvol and Uvol by interval
Time frame: Up to Day 10
Correlation Coefficient Between 24-Hour Uvol and Uosm by Interval
Time frame: Up to Day 10
Correlation Coefficient Between 24-Hour Uvol and Spot Uosm
Time frame: Up to Day 10
Correlation Coefficient Between Change From Baseline in Uvol and Change From Baseline in Uosm by Interval
Time frame: Up to Day 10
Number of Participants With Adverse Events (AEs)
Time frame: Up to Day 39
Number of Participants With Clinically Relevant Changes in Clinical Laboratory Values
Time frame: Up to Day 31
Number of Participants With Potentially Clinically Relevant Changes in Vital Signs
Time frame: Up to Day 31
Number of Participants With Clinically Significant Abnormalities in Physical Examination Findings
Time frame: Up to Day 10
Number of Participants With Potentially Clinically Significant Changes in 12-lead Electrocardiogram (ECG) Parameters
Time frame: Up to Day 10
Maximum (Peak) Plasma Concentration (Cmax) of NDI-5001
Time frame: Day 1 and Day 9
Time to Reach Maximum (Peak) Observed Plasma Concentration (Tmax) of NDI-5001
Time frame: Day 1 and Day 9
Area Under the Concentration-time Curve From Time Zero to 24 hours (AUC0-24h) of NDI-5001
Time frame: Up to 24 hours, post dose on Day 1 and Day 9
Dose-Normalized Maximum Observed Plasma Concentration (Cmax/Dose) of NDI-5001
Time frame: Day 1 and Day 9
Dose-Normalized Area Under the Plasma Concentration-Time Curve From 0 to 24 Hours (AUC0-24h/Dose) of NDI-5001
Time frame: Up to 24 hours, post dose on Day 1 and Day 9
Plan to share: No
Started Jul 2026 (actual). Primary completion is estimated for Aug 2027, 13 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Otsuka Pharmaceutical Development & Commercialization, Inc. →